AVDL News and Press, Avadel Pharmaceuticals plc From 11/05/21

Avadel Pharmaceuticals (NASDAQ:AVDL) is scheduled to announce Q3 earnings results on Friday, November 5th, after market close. The consensus EPS Estimate is -$0.38 (-90.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 d...

AVDL, AXSM, BKI, COTY, CTRE, DS,EDIT, EHTH, IMOS, KOS, LINC, LTBR, MTNB, NERV, OCN, PSEC, RDUS, RETA, TGLS, THS, TSEM, TTD, TYME, USFD, VAC, VTRS, WOW For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corpor...

FT218 PDUFA was delayed by the FDA, reasons unknown, suspected staffing issues at the agency. FT218 has a clear advantage over Xyrem. I am holding tight. For further details see: Avadel Pharmaceuticals: I Am Holding

Shares of Jazz Pharmaceuticals have been under pressure in the last few months on what appears to be investor concern about the durability of the company’s narcolepsy franchise. The threats are real - new narcolepsy drugs and primarily Xyrem going generic in 2023, and the high ...

- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compared to placebo - - Discrete choice experiment demonstrated that the strongest r...

Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) are down 14% as of 1:29 p.m. EDT today after the Food and Drug Administration said it would need more time than originally thought to review FT218 -- Avadel's candidate to treat narcolepsy. After accepting a company's approval ...

Analysts' notes and drug development headlines inspired significant stock movement in Monday's midday trading. This included one of the world's biggest entertainment conglomerates, with Disney (NYSE:DIS) losing ground in the wake of a downgrade from Barclays. Upstart (NASDAQ:UPST) also dipped...

Revance Therapeutics (NASDAQ:RVNC) -33% after FDA declines to approve wrinkle injection. MannKind (NASDAQ:MNKD) -18% as FDA declines to approve United Therapeutics’ heart disease drug Omeros (NASDAQ:OMER) -17% after FDA fails to approve narsoplimab treatme...

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug Administration (FDA) notified the company that the review of the New Drug Application (ND...